CL2012002685A1 - Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar; vacuna que comprende la composicion; uso de la composicion para tratar o prevenir demencia y enfermedad de alzheimer. - Google Patents
Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar; vacuna que comprende la composicion; uso de la composicion para tratar o prevenir demencia y enfermedad de alzheimer.Info
- Publication number
- CL2012002685A1 CL2012002685A1 CL2012002685A CL2012002685A CL2012002685A1 CL 2012002685 A1 CL2012002685 A1 CL 2012002685A1 CL 2012002685 A CL2012002685 A CL 2012002685A CL 2012002685 A CL2012002685 A CL 2012002685A CL 2012002685 A1 CL2012002685 A1 CL 2012002685A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- alzheimer
- vaccine
- virus
- beta
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158273 | 2010-03-29 | ||
| US36169710P | 2010-07-06 | 2010-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002685A1 true CL2012002685A1 (es) | 2013-01-25 |
Family
ID=42285305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002685A CL2012002685A1 (es) | 2010-03-29 | 2012-09-27 | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar; vacuna que comprende la composicion; uso de la composicion para tratar o prevenir demencia y enfermedad de alzheimer. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20130011431A1 (enExample) |
| EP (1) | EP2552489A1 (enExample) |
| JP (2) | JP6088422B2 (enExample) |
| KR (1) | KR20130018407A (enExample) |
| CN (2) | CN104436212A (enExample) |
| AR (1) | AR080810A1 (enExample) |
| AU (1) | AU2011234656B2 (enExample) |
| BR (1) | BR112012024708A2 (enExample) |
| CA (1) | CA2793580A1 (enExample) |
| CL (1) | CL2012002685A1 (enExample) |
| CO (1) | CO6630127A2 (enExample) |
| EC (1) | ECSP12012180A (enExample) |
| GT (1) | GT201200265A (enExample) |
| IL (1) | IL221540B (enExample) |
| MA (1) | MA34084B1 (enExample) |
| MX (1) | MX2012011340A (enExample) |
| NZ (1) | NZ601729A (enExample) |
| PE (1) | PE20130642A1 (enExample) |
| PH (1) | PH12012501683A1 (enExample) |
| RU (1) | RU2603486C2 (enExample) |
| SG (2) | SG183806A1 (enExample) |
| TN (1) | TN2012000431A1 (enExample) |
| TW (2) | TW201618806A (enExample) |
| WO (1) | WO2011120924A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| CN106535924A (zh) * | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015165966A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| WO1999002132A2 (en) * | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| WO2003009869A1 (en) * | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
| RU2450827C2 (ru) * | 2002-07-19 | 2012-05-20 | Цитос Биотехнологи Аг | Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6 |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| BRPI0516953A (pt) * | 2004-09-21 | 2008-09-30 | Cytos Biotechnology Ag | partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 PH PH1/2012/501683A patent/PH12012501683A1/en unknown
- 2011-03-28 CA CA2793580A patent/CA2793580A1/en not_active Abandoned
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
- 2011-03-28 EP EP11711322A patent/EP2552489A1/en not_active Withdrawn
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Ceased
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/en not_active Ceased
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012002685A1 (es) | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar; vacuna que comprende la composicion; uso de la composicion para tratar o prevenir demencia y enfermedad de alzheimer. | |
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| MX2017002954A (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol. | |
| ECSP13012534A (es) | Composición farmacéutica | |
| AR082688A1 (es) | Uso de aglomerantes para preparar formulaciones estables al almacenamiento | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2013003146A1 (es) | Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria. | |
| CL2012002489A1 (es) | Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c. | |
| CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
| AR077629A1 (es) | Mimetico de smac | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| CR20150337A (es) | Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral | |
| NI201600093A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CR10561A (es) | Vacunas para malaria | |
| CL2014001016A1 (es) | Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. | |
| GT201700124A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| CL2014001337A1 (es) | Formulacion farmaceutica oral solida que comprende una dispersion solida que comprende a su vez un compuesto especifico derivado de 4-(1-isopropil-1h-pirazol-4-il)-pirimidina y su uso en el tratamiento de una enfermedad proliferativa. | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CL2014000394A1 (es) | Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos. |